2024-10-25 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

### 1. Performance Comparison

Abbott Laboratories (ABT) is a global healthcare company that develops, manufactures, and markets a wide range of medical devices, diagnostics, nutrition, and pharmaceuticals. 

* **Cumulative Return:** ABT has delivered a cumulative return of 108.65%, while the S&P 500 (VOO) has delivered a return of 135.48%. 
* **Performance Gap:** This represents a difference of -26.83%. 
* **Relative Performance:** This places ABT in the 15.19th percentile compared to its historical performance range (with a maximum of 65.94% and a minimum of -46.17%). This indicates that while ABT has underperformed the S&P 500, it is not significantly lagging behind its historical performance. 

### 2. Recent Price Movement

* **Closing Price:** $116.54
* **5-Day Moving Average:** $117.39
* **20-Day Moving Average:** $115.53
* **60-Day Moving Average:** $113.68

The stock is currently trading slightly below its 5-day moving average, suggesting a slight short-term bearish bias. However, the stock is trading above its 20 and 60-day moving averages, indicating a long-term bullish trend.

### 3. Technical Indicators

* **RSI:** 65.83 - This indicates that ABT is in the overbought territory, suggesting potential for a short-term correction. 
* **PPO:** 0.02 - This indicates a slightly bullish momentum, but it is very close to the neutral level.
* **Delta_Previous_Relative_Divergence:** +3.96 - This indicates a short-term upward momentum.
* **Expected Return:** 0.0% - This indicates that the stock is expected to perform in line with the S&P 500 over the long term (2 years or more).

**Note:**  The current price of $116.54 does not suggest any significant price jump or fall. It is trading within a relatively stable range.

### 4. Recent Earnings & Outlook

| Date       | EPS    | Revenue           |
|------------|--------|--------------------|
| 2024-07-31 | 0.74   | $10.38 Billion     |
| 2024-05-02 | 0.7    | $9.96 Billion      |
| 2023-11-01 | 0.82   | $10.14 Billion     |
| 2023-08-03 | 0.79   | $9.98 Billion      |
| 2024-07-31 | 0.79   | $9.98 Billion      |

* **Latest Earnings:** The latest earnings report for Q2 2024 showed EPS of $0.74, which beat analysts' expectations of $0.72. Revenue also exceeded expectations, coming in at $10.38 billion compared to the estimated $10.29 billion. 
* **Outlook:**  Analysts are generally positive about ABT's future prospects, citing continued strong demand for its products and services, as well as its commitment to innovation. However, they have cautioned about potential headwinds from rising inflation and supply chain disruptions.

### 5. News & Recent Events

* **Earnings Announcement:** ABT recently announced its Q2 2024 earnings, exceeding analysts' expectations for both EPS and revenue. This positive result has generally been well-received by market analysts. 
* **Market Outlook:** ABT is considered a stable and reliable company in the healthcare sector. Analysts expect it to continue its growth in the long term, driven by the aging population and rising demand for healthcare solutions.
* **Analyst Opinions:** Analysts are generally bullish on ABT, with many rating the stock as a "buy" or "hold".  FINBOLD, for example, reported that the average target price for ABT is $124.74, suggesting a potential upside of 7.0%.

### 6. Overall Analysis

ABT is a well-established healthcare company with a strong track record of performance and a positive future outlook. While it has underperformed the S&P 500 in recent years, it remains a solid investment option for long-term investors. Its recent earnings beat and positive analyst outlook suggest that the company is well-positioned to continue its growth trajectory. 

However, potential headwinds from inflation and supply chain issues could impact its future performance. Investors should closely monitor the company's progress and its ability to navigate these challenges. 

### 7. Recommendation

Based on the current analysis, ABT appears to be a **solid long-term investment** for investors seeking exposure to the healthcare sector. It is a stable and reliable company with a solid track record and promising growth prospects. However, investors should consider its current overbought condition (as indicated by RSI) and potential headwinds from external factors.  


**Disclaimer:** This analysis is for informational purposes only and should not be considered as investment advice. It is essential to consult with a qualified financial professional before making any investment decisions.
